A blend certificate for BPC-157 and TB-500 should report two molecular weights and two net contents. If it reports one of either, it has not shown that both compounds are present — and the two masses it does report should match the single-compound certificates exactly.
Blends are where certificate reading gets genuinely harder, because a single purity figure describes a chromatogram with two peaks in it and that number alone cannot tell you the ratio. This post covers what the document should contain, the arithmetic that confirms it, and what blending does and does not change about either molecule.
What the certificate reports
| Field | Lot BPCTB20-0616 |
|---|---|
| Identity | Wolverine Blend (BPC-157 + TB-500) |
| Molecular weights | 1419.5, 4964.2 |
| Net content | 10.72 mg, 10.16 mg |
| Purity (RP-HPLC, 214 nm) | 99.9% |
| Endotoxin | <0.05 EU/mL |
| Label | 20 mg |
Four of those lines need reading differently from a single-compound certificate.
The cross-check that takes ten seconds
The two masses should be the same numbers the individual certificates report. They are:
| Component | Blend certificate | Single-compound certificate | Match |
|---|---|---|---|
| BPC-157 | 1419.5 | 1419.5 (lots BP5/BP10/BP15-0803) | ✓ |
| TB-500 | 4964.2 | 4964.2 (lot TB10-0803) | ✓ |
This is worth doing every time, on any multi-component certificate, because it is the single most informative check available to a reader and it requires no equipment. A mass that matches neither component is a document problem, whether that means a transcription error, a page from the wrong lot, or something else. You cannot diagnose which from the outside — but you can see that the arithmetic fails, and that is enough to ask.
The same logic extends to larger blends. A four-component certificate should carry four masses, each matching a known compound. For the GLOW mix and the KLOW blend the component masses decode the formulation completely.
Why net content is reported twice
Because "20 mg" on the label describes the vial, not either compound.
10.72 mg of BPC-157 plus 10.16 mg of TB-500 is 20.88 mg total — a nominal 10 mg of each, both slightly over, consistent with the deliberate overfill seen across this catalogue. Net peptide content vs purity explains why net content and label quantity routinely differ, and why the gap is expected rather than concerning.
Note the ratio is approximately 1:1 by mass, not by moles. TB-500 is 3.5 times heavier than BPC-157, so equal masses mean roughly 3.5 times more BPC-157 molecules in the vial. Anyone working in molar terms needs to do that conversion themselves — molarity vs milligrams covers the arithmetic.
What a single purity figure can and cannot tell you
99.9% on a blend means the two expected peaks together account for 99.9% of the absorbance area at 214 nm. Everything else — all impurities from both synthesis routes combined — is the remaining 0.1%.
What it does not tell you:
- The ratio between the two components. Area percent depends on how strongly each molecule absorbs at 214 nm, and a 43-residue protein and a 15-residue peptide do not absorb equally. Peak areas are not proportional to mass.
- Whether one component is degraded while the other is intact. A degradation product co-eluting with either peak would be invisible.
- Whether both peaks are the compounds claimed. That is the identity line's job, not purity's.
HPLC purity as area percent covers the absorbance issue in detail. The practical consequence for blends is simply that purity and ratio are different questions, and only net content answers the second.
What blending changes
Chemically, nothing. The two compounds are lyophilized together or combined as powders; they are not conjugated, complexed or reacted. Each retains its own mass, its own chromatographic behaviour and its own stability profile.
| Question | Blend behaviour |
|---|---|
| Reconstitution | As for the less soluble component; both dissolve readily here |
| Stability | Each component degrades on its own pathway and at its own rate |
| Storage | Standard lyophilized handling, how to store peptide vials |
| Aliquoting | Both components aliquot together; the ratio stays fixed |
| Analysis | Two peaks, two masses, one purity figure |
The one genuine consequence of blending is loss of independent control. Once two compounds share a vial you cannot vary one without the other, cannot test them separately from that material, and cannot attribute an observation to either. For any experiment where attribution matters, single-compound vials are the correct choice — peptide blends vs single compounds covers that trade-off.
Why these two are paired
Convention rather than pharmacology. They are unrelated molecules: BPC-157 is a 15-residue synthetic peptide with a contested gastric origin; TB-500 as supplied is full-length thymosin β4, a 43-residue intracellular actin-sequestering protein. They share no sequence, no proposed mechanism, and no common literature.
The pairing became standard in the research-compound market and the blend acquired an informal trade name, which is what appears on the identity line. The certificates for the individual compounds — BPC-157 and TB-500 — cover each molecule on its own terms.
Neither compound is approved in any major jurisdiction. BPC-157 sits in FDA 503A Category 2; TB-500 is prohibited in sport under WADA's S2 class. Both are supplied for laboratory research only, and what "research use only" means covers what that designation does.
Frequently asked questions
Why does the certificate show two molecular weights?
Because there are two molecules. Each is confirmed separately by mass spectrometry. A blend certificate with one mass has only confirmed one component.
Does 99.9% purity apply to each compound separately?
No. It is one figure for the whole chromatogram. There is no per-component purity on a blend certificate of this type.
How do I know the ratio is what the label says?
From the net content line, not the purity line. Two contents of 10.72 mg and 10.16 mg against a 20 mg label indicate a nominal 1:1 blend by mass.
What should I do if the masses do not match the individual compounds?
Ask the supplier before using the material. A mass that corresponds to neither component means the document does not describe what it claims to, and that is a question the supplier should be able to answer directly. How to verify a certificate of analysis covers the full check.
Is a blend cheaper than buying both separately?
Usually, because it is one vial, one lyophilization run and one certificate. The saving is in processing, not in material.
Can I separate the two compounds after reconstitution?
Not without preparative chromatography. For practical purposes a blend is permanent once it is in the vial.
References
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 2011;17(16):1612-32. doi.org/10.2174/138161211796196936
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine 2005;11(9):421-9. doi.org/10.1016/j.molmed.2005.07.004
- United States Pharmacopeia. General Chapter <621> Chromatography. www.usp.org
Every product mentioned is sold for laboratory research use only and is not for human or animal use. Nothing on this page describes or recommends use of the material sold here in humans or animals.
